Table 1.

Characteristics of patients by HBsAg seroclearance in the entire and propensity score-matched cohorts

Entire cohortPropensity score-matched cohort (1:4 pairs)
CharacteristicsHBsAg seroclearanceNo HBsAg seroclearancep ValueHBsAg seroclearanceNo HBsAg seroclearancep Value
N110529993372
Age*, years42±1045±110.0242±1044±110.32
Male, n (%)84 (76.4)3615 (68.2)0.3172 (77.4)261(70.2)0.17
HBeAg-positive, n (%)55 (50.0)3546 (66.9)0.0152 (55.9)224 (60.2)0.45
HBV DNA*, log10 IU/mL5.9±2.77.4±1.4<0.017.3±1.37.0±1.30.06
ALT†, IU/L154 (67–340)115 (62–225)0.03182 (101–399)135 (61–257)0.45
Albumin†, g/dL4.0 (3.5–4.2)3.8 (3.3–4.1)0.024.0 (3.5–4.1)3.9 (3.4–4.2)0.53
Bilirubin†, mg/dL1.2 (1.0–1.8)1.2 (0.9–1.6)0.081.1 (1.0–1.6)1.1 (0.8–1.5)0.70
INR†1.18 (1.00–1.17)1.10 (1.00–1.20)0.951.08 (1.00–1.18)1.10 (1.00–1.20)0.21
Platelet† (×103/μL)151 (100–190)144 (96–190)0.69151 (105–190)161 (121–202)0.08
Cirrhosis, n (%)34 (30.9)2650 (50.0)<0.0129 (31.2)136 (36.6)0.33
Antiviral therapy<0.010.08
 Lamivudine, n (%)107 (97.3)3301 (62.3)90 (96.8)339 (91.1)
Entecavir, n (%)3 (2.7)1998 (37.7)3 (3.2)33 (8.9)
Selection for drug-resistance HBV mutants‡, n (%)37 (33.6)1711 (32.3)0.7736 (38.7)138 (37.1)0.77
Overall treatment duration†, years4.3 (2.1–6.8)4.0 (2.1–7.1)0.914.2 (2.1–6.9)5.3 (2.2–9.6)<0.01
Overall follow-up period†, years9.8 (7.5–12.0)6.0 (3.3–9.5)<0.019.6 (7.7–11.9)9.6 (6.5–11.9)0.06
  • Characteristics of patients are at the initiation of antiviral therapy unless specified.

  • Cirrhosis was diagnosed when ultrasonography or CT scanning revealed liver surface nodularity with splenomegaly.

  • Propensity scores were derived from the variables at the treatment initiation and were matched for the patients with and without HBsAg seroclearance (1:4).

  • *mean±SD.

  • †median (IQR).

  • ‡During antiviral therapy before HBsAg seroclearance.

  • ALT, alanine aminotransferase; INR, international normalised ratio.